Phosphorylated tau (p-tau) biomarkers have emerged as critical tools in the differential diagnosis of systemic amyloidosis, particularly immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. This comprehensive review examines the emerging evidence that blood p-tau elevation serves as a valuable biomarker not only for Alzheimer's disease but also for systemic amyloidosis involving the central nervous system. The implications for differential diagnosis, disease staging, and treatment monitoring are substantial, as clinicians now have non-invasive biomarkers to distinguish between primary tauopathies and secondary tau involvement due to systemic amyloid deposition.
Amyloidosis represents a group of diseases characterized by extracellular deposition of misfolded proteins in various tissues and organs. The two most clinically significant forms affecting the nervous system are AL amyloidosis (immunoglobulin light chain) and ATTR amyloidosis (transthyretin). These systemic diseases can involve the central nervous system (CNS), creating diagnostic challenges that overlap with primary neurodegenerative conditions like Alzheimer's disease.
AL amyloidosis results from misfolded immunoglobulin light chains produced by clonal plasma cells. These toxic proteins can deposit in multiple organs, including the heart, kidneys, liver, and nervous system. The estimated incidence of AL amyloidosis is approximately 10-12 per million person-years, making it the most common form of systemic amyloidosis in developed countries. [@amyloidosis2024]
ATTR amyloidosis results from misfolded transthyretin protein, either due to inherited mutations (hereditary ATTR) or age-related wild-type deposition (wild-type ATTR, previously called senile systemic amyloidosis). Over 120 TTR mutations have been identified, each with distinct clinical phenotypes. The V30M mutation is the most common hereditary form, while wild-type ATTR predominantly affects the heart in elderly males. [@genetics2024]
Tau protein, a microtubule-associated protein primarily expressed in neurons, plays a crucial role in maintaining neuronal structure and function. In Alzheimer's disease, hyperphosphorylated tau accumulates as neurofibrillary tangles, correlating closely with cognitive decline. However, tau pathology can also occur secondary to other brain insults, including traumatic brain injury, stroke, and notably — systemic amyloid deposition.
The recognition that p-tau can be elevated in systemic amyloidosis due to indirect effects on neuronal health has important diagnostic implications. Clinicians must now consider whether elevated p-tau reflects primary AD pathology, secondary tau changes due to systemic amyloidosis, or both in cases of mixed pathology. [@ptau2024]
Tau is encoded by the MAPT (Microtubule-Associated Protein Tau) gene located on chromosome 17q21.31. The protein exists in six isoforms in the human brain, ranging from 352 to 441 amino acids, generated by alternative splicing of exons 2, 3, and 10. The isoforms differ in the number of microtubule-binding repeats (3 or 4), which affects tau's ability to bind and stabilize microtubules.
Tau function is critically regulated by phosphorylation. Over 80 potential phosphorylation sites have been identified on tau, including serine, threonine, and tyrosine residues. Physiologically, tau phosphorylation is dynamic and regulated by a balance between kinases (including GSK-3β, CDK5, and MAPK) and phosphatases (primarily PP1, PP2A, and PP2B). In disease states, this balance shifts toward hyperphosphorylation, reducing tau's microtubule-binding capacity and promoting aggregation. [@csf2024]
Several p-tau isoforms have been characterized as biomarkers:
p-tau181: The most extensively studied p-tau species. Elevated in AD from preclinical stages and shows strong correlation with AD diagnosis. Sensitive to amyloid pathology, making it useful for early detection.
p-tau217: Shows even stronger specificity for AD than p-tau181. Correlates with both amyloid and tau pathology. The Swedish BioFINDER study demonstrated superior diagnostic performance for p-tau217 in distinguishing AD from other dementias. [@ptau2172024]
p-tau231: Elevates earliest among p-tau species, potentially reflecting initial tau pathology. Useful for detecting very early (preclinical) AD changes.
p-tau205: Less commonly measured but provides complementary information about tau pathology burden.
In healthy individuals, tau is present in CSF at concentrations of approximately 200-400 pg/mL. Total tau (t-tau) reflects neuronal damage, while phosphorylated tau (p-tau) specifically indicates pathological tau processing. The blood-brain barrier maintains distinct compartments, but recent advances in ultrasensitive assay technologies have enabled reliable p-tau measurement in plasma. [@assay2024]
The elevation of p-tau in AL amyloidosis reflects several interconnected pathophysiological mechanisms:
Direct Neuronal Toxicity: Light chain amyloid fibrils can exert direct toxic effects on neurons. In vitro studies have demonstrated that soluble oligomers of light chains can disrupt neuronal membranes, induce oxidative stress, and trigger apoptotic pathways. This neuronal damage releases tau into the extracellular space and ultimately into CSF and blood.
Vascular Amyloid Deposition: AL amyloidosis commonly involves cerebral vasculature, leading to cerebral amyloid angiopathy (CAA). Amyloid deposition in small vessels compromises blood-brain barrier integrity, potentially allowing p-tau to leak into peripheral circulation while also causing secondary neuronal injury. [@brain2024]
Microvascular Damage: Amyloid deposition in cerebral microvasculature reduces cerebral blood flow and can cause microinfarcts. Chronic hypoperfusion and ischemia-reperfusion injury contribute to neuronal damage and p-tau release.
Systemic Inflammation: AL amyloidosis triggers profound systemic inflammation, including elevated cytokines and acute-phase reactants. Neuroinflammation can accelerate tau phosphorylation through kinase activation and phosphatase inhibition.
A key study (PMID:41814005) demonstrated elevated p-tau levels in patients with AL amyloidosis compared to controls. The elevation was modest compared to AD but statistically significant, suggesting secondary tau pathology rather than primary neurodegenerative disease. Importantly, p-tau levels correlated with measures of cardiac involvement, suggesting that systemic amyloid burden may influence CNS biomarker levels. [@ptau2025]
Another important finding is that p-tau elevation in AL amyloidosis appears to be lower than in AD, potentially allowing for differentiation. The pattern of p-tau isoforms may also differ: AL amyloidosis shows a different p-tau181/p-tau217 ratio compared to AD, though this requires further validation.
For clinicians evaluating patients with suspected AL amyloidosis and cognitive symptoms:
| Scenario | p-tau Level | Likely Etiology |
|----------|-------------|-----------------|
| AL amyloidosis, no cognitive symptoms | Normal to mildly elevated | Primary disease effect |
| AL amyloidosis with cognitive symptoms | Moderately elevated | Mixed: amyloid + secondary tau |
| AL amyloidosis with high p-tau | Very high | Consider coincident AD |
The diagnostic challenge arises when patients have both AL amyloidosis and AD (common in elderly populations). In such cases, p-tau levels may be very high, reflecting additive pathology. Amyloid PET imaging can help differentiate primary AD amyloid from systemic AL amyloid deposition. [@pet2024]
ATTR amyloidosis affects the nervous system through both direct deposition and secondary effects:
Direct CNS Deposition: TTR amyloid can deposit in the leptomeninges and cerebral vasculature. The TTR molecule has natural tendency to form amyloid fibrils, and when it reaches the CNS, it can cause direct neuronal dysfunction.
Autonomic Neuropathy: ATTR commonly causes autonomic dysfunction through peripheral neuropathy. Autonomic impairment can affect blood pressure regulation, potentially influencing cerebral perfusion and contributing to secondary neuronal injury.
Mixed Pathology: Wild-type ATTR predominantly affects elderly individuals who also have high AD prevalence. Many patients with wild-type ATTR have co-existing AD pathology, making biomarker interpretation complex. [@catr2024]
Research (PMID:39274021) demonstrated p-tau elevation in ATTR amyloidosis, with distinct patterns based on genotype:
Hereditary ATTR (hATTR): Patients with V30M mutations, the most common hereditary form, show p-tau elevation that correlates with disease duration and neurological involvement. Earlier-onset mutations (V30M) may show different patterns compared to later-onset variants.
Wild-Type ATTR (wtATTR): Formerly called senile systemic amyloidosis, wild-type ATTR predominantly affects the heart in men over 70. P-tau elevation is common, often reflecting co-existing AD pathology given the age demographic.
P-tau levels in ATTR amyloidosis correlate with cardiac biomarkers, including troponin and NT-proBNP. This suggests that systemic amyloid burden influences CNS biomarker levels. The heart-brain connection in amyloidosis highlights the systemic nature of these diseases. [@cardiol2025]
Understanding the distinct biomarker patterns helps clinicians distinguish primary from secondary tau elevation:
| Biomarker | AL Amyloidosis | ATTR Amyloidosis | Alzheimer's Disease |
|-----------|-----------------|------------------|---------------------|
| p-tau181 | Mild-moderate elevation | Mild-moderate elevation | Very high elevation |
| p-tau217 | Moderate elevation | Moderate elevation | Very high elevation |
| t-tau | Normal to mildly elevated | Normal to mildly elevated | High elevation |
| Aβ42/40 | Variable (usually normal) | Variable (usually normal) | Decreased |
| NfL | Elevated | Elevated | Elevated |
| Neurofilament light | Elevated | Elevated | Elevated |
A practical approach to differential diagnosis incorporates multiple biomarkers:
Amyloid PET imaging shows decreased uptake in AL amyloidosis (negative amyloid PET) because the amyloid deposits are primarily composed of light chains, not Aβ. This is a key differentiator from AD, where amyloid PET is typically positive. However, ATTR patients with co-existing AD will have positive amyloid PET due to AD pathology.
P-tau levels may serve as markers of disease severity in systemic amyloidosis:
P-tau may serve as a biomarker for treatment response in amyloidosis:
AL Amyloidosis Treatment Monitoring:
Elevated p-tau in systemic amyloidosis is associated with:
NfL is a marker of neuroaxonal damage, elevated in numerous neurological conditions. In amyloidosis:
Amyloid beta biomarkers show distinct patterns:
The cardiac-neuro connection in amyloidosis:
The elevation of p-tau in systemic amyloidosis involves multiple mechanisms:
Amyloid-Induced Neuroinflammation:
Tau pathology in amyloidosis may show regional patterns:
Current treatment approaches for AL amyloidosis:
Chemotherapy:
ATTR treatment options have expanded dramatically:
TTR Stabilizers:
Several emerging biomarkers may complement p-tau:
Tau Fragments: Specific tau fragments (e.g., eMTBR-tau243) may provide additional information about tau pathology type and location.
Exosomal Tau: Tau in neuronal exosomes may represent early markers of neuronal injury.
Phospho-Tau Isoforms: More specific p-tau species (p-tau217, p-tau231) are being validated in amyloidosis.
Multi-Marker Panels: Combination of p-tau, NfL, GFAP, and other markers may improve diagnostic accuracy.
Ongoing clinical trials are incorporating p-tau as:
Large-scale validation studies are needed to:
Several challenges exist in using p-tau for amyloidosis:
Potential solutions include:
Phosphorylated tau biomarkers have evolved from being specific markers of Alzheimer's disease to important tools in the broader differential diagnosis of cognitive impairment in patients with systemic amyloidosis. The recognition that p-tau can be elevated in AL and ATTR amyloidosis, albeit through different mechanisms than primary AD, has important clinical implications.
Key takeaways for clinicians:
As assay technologies improve and clinical experience accumulates, p-tau will likely become an integral part of the diagnostic and monitoring approach for patients with systemic amyloidosis and cognitive symptoms.